PM1183 plus doxorubicin shows interesting activity in small cell lung cancer
2 مناظر
• 07/14/23
0
0
ایمبیڈ
administrator
سبسکرائبرز
Visit http://www.ecancer.org for more
Dr Calvo (START Madrid, Madrid, Spain) talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)
مزید دکھائیں
فیس بک کے تبصرے
SORT BY-
سرفہرست تبصرے
-
تازہ ترین تبصرے